Physician profile
Dai Chu Nguyen Luu
NPI 1639498314
$90,289.54
in general payments reported to CMS, 2019-2025
62 companies · $3,746 in 2025
The $3,746 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,439 · 2020: $4,599 · 2021: $24K · 2022: $19K · 2023: $28K · 2024: $6,867 · 2025: $3,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $6,052 · Travel and Lodging: $3,495 · Honoraria: $2,700 · Consulting Fee: $2,532 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,850.00 |
| Food and Beverage | $6,052.20 |
| Travel and Lodging | $3,495.47 |
| Honoraria | $2,700.00 |
| Consulting Fee | $2,532.00 |
| Education | $383.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $43,484.60 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Taiho Oncology, INC. | $26,497.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,782.60 | 2020-2025 | Imfinzi, Calquence, Enhertu |
| Rigel Pharmaceuticals, INC. | $2,619.63 | 2019 | |
| Pharmacosmos Therapeutics INC. | $2,561.40 | 2024 | Monoferric |
| Cti Biopharma Corp. | $1,725.00 | 2022 | |
| Pfizer INC. | $1,348.09 | 2019-2025 | |
| Kite Pharma, INC. | $1,197.19 | 2019-2025 | Yescarta |
| Janssen Biotech, INC. | $892.02 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Exelixis INC. | $740.00 | 2020 | |
| Merck Sharp & Dohme LLC | $555.49 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $545.05 | 2023-2025 | Enhertu, Datroway |
| Beigene, Ltd. | $525.00 | 2021 | |
| Abbvie INC. | $256.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $177.48 | 2022-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $169.32 | 2024 | Xt Cdx |
| Gilead Sciences, INC. | $168.84 | 2021-2025 | Trodelvy |
| Genentech USA, INC. | $158.32 | 2023-2025 | Tecentriq, Xolair, Lunsumio |
| Incyte Corporation | $145.13 | 2019-2025 | Jakafi |
| Regeneron Healthcare Solutions, INC. | $144.45 | 2025 | Libtayo, Lynozyfic |
| Celgene Corporation | $142.52 | 2022-2024 | Pomalyst, Reblozyl |
| Genzyme Corporation | $132.40 | 2022-2024 | |
| Seagen INC. | $119.52 | 2019-2023 | Tukysa |
| Myriad Genetic Laboratories, INC. | $114.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.42 | 2019-2024 | Fruzaqla, Vonvendi, Alunbrig |
| Helsinn Therapeutics (U.S.), INC. | $111.35 | 2022-2023 | Akynzeo |
| Amgen INC. | $109.53 | 2019-2023 | Lumakras, Blincyto |
| Pharmacyclics LLC, An Abbvie Company | $108.23 | 2019 | |
| Aveo Pharmaceuticals, INC. | $107.76 | 2023-2025 | Fotivda |
| Karyopharm Therapeutics INC. | $100.95 | 2021-2025 | Xpovio |
| Eisai INC. | $95.04 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $89.00 | 2022 | |
| Emd Serono, INC. | $87.73 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.17 | 2022-2024 | |
| Glaxosmithkline, LLC. | $86.30 | 2022-2025 | Ojjaara |
| Array Biopharma INC | $83.93 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Astellas Pharma US INC | $81.88 | 2019-2024 | Vyloy |
| Pharmaessentia USA Corporation | $80.68 | 2023-2025 | Besremi |
| Sobi, INC | $75.84 | 2022-2025 | |
| Lilly USA, LLC | $56.42 | 2022-2024 | Retevmo, Jaypirca, Verzenio |
| Syndax Pharmaceuticals, INC. | $51.55 | 2025 | |
| Tersera Therapeutics LLC | $48.59 | 2019-2021 | |
| Geron Corporation | $47.87 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $46.38 | 2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $46.21 | 2025 | Ultomiris |
| Adc Therapeutics America, INC. | $38.74 | 2023-2024 | |
| Immunocore Limited | $29.45 | 2025 | Kimmtrak |
| Beigene USA, INC. | $26.38 | 2023 | Brukinsa |
| Janssen Pharmaceuticals, INC | $25.75 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $24.60 | 2024 | Onivyde |
| Springworks Therapeutics, INC. | $24.20 | 2024 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $21.75 | 2025 | |
| Menarini Silicon Biosystems, INC. | $20.87 | 2024 | |
| G1 Therapeutics, INC. | $20.54 | 2021 | |
| Novocure INC. | $19.35 | 2022 | |
| Puma Biotechnology, INC. | $19.12 | 2021 | |
| Clovis Oncology, INC. | $19.05 | 2022 | |
| Caris Mpi, INC. | $18.57 | 2025 | Mi Cancer Seek |
| Blueprint Medicines Corporation | $17.92 | 2021 | |
| Tesaro, INC. | $16.55 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.42 | 2019 | |
| Verastem, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dai Chu Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.